{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Li T"],"funding":["The Haiyan Fund Project","National Natural Science Foundation of China","Postgraduate Research &amp; Practice Innovation Program of Harbin Medical University"],"pagination":["e010534"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11590841"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(11)"],"pubmed_abstract":["<h4>Background</h4>Despite the success of immune checkpoint inhibitor (ICI)-based combination therapies in hepatocellular carcinoma (HCC), its effectiveness remains confined to a subset of patients. The development of reliable, predictive markers is important for accurate patient stratification and further mechanistic understanding of therapy response.<h4>Methods</h4>We comprehensively analyzed paired single-cell RNA transcriptome and T-cell repertoire profiles from 14 HCC ascites samples, collected from 7 patients before and after treatment with the combination of sintilimab (anti-PD-1) and bevacizumab (anti-VEGF).<h4>Results</h4>We identify a widespread convergence on interferon (IFN) signaling across various immune cell lineages in treatment-responsive patients with HCC, indicating a co"],"journal":["Journal for immunotherapy of cancer"],"pubmed_title":["Integrated single-cell transcriptome and TCR profiles of hepatocellular carcinoma highlight the convergence on interferon signaling during immunotherapy."],"pmcid":["PMC11590841"],"funding_grant_id":["82273492","82394454","YJSCX2024-12HYD","JJMS2023-01"],"pubmed_authors":["Hou Z","Xu C","Zhang M","Kong D","Wang G","Guo S","Lyu C","Xu H","Li X","Li T","Ren J","Liu C","Hao D"],"additional_accession":[]},"is_claimable":false,"name":"Integrated single-cell transcriptome and TCR profiles of hepatocellular carcinoma highlight the convergence on interferon signaling during immunotherapy.","description":"<h4>Background</h4>Despite the success of immune checkpoint inhibitor (ICI)-based combination therapies in hepatocellular carcinoma (HCC), its effectiveness remains confined to a subset of patients. The development of reliable, predictive markers is important for accurate patient stratification and further mechanistic understanding of therapy response.<h4>Methods</h4>We comprehensively analyzed paired single-cell RNA transcriptome and T-cell repertoire profiles from 14 HCC ascites samples, collected from 7 patients before and after treatment with the combination of sintilimab (anti-PD-1) and bevacizumab (anti-VEGF).<h4>Results</h4>We identify a widespread convergence on interferon (IFN) signaling across various immune cell lineages in treatment-responsive patients with HCC, indicating a co","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Nov","modification":"2026-06-01T12:50:15.712Z","creation":"2025-04-04T01:20:00.541Z"},"accession":"S-EPMC11590841","cross_references":{"pubmed":["39581706"],"doi":["10.1136/jitc-2024-010534"]}}